Metavia INC. (MTVA) — SEC Filings

Overview

Metavia INC. (MTVA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 7, 2026: MetaVia Inc. filed an EFFECT form with the SEC on April 7, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001091, relates to Act 33 and File No. 333-280865. The company's mailing and business address is 545 Concord Avenue, Suite 210, C

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 46 neutral. The dominant filing sentiment for Metavia INC. is neutral.

Filing Type Overview

Metavia INC. (MTVA) has filed 33 8-K, 1 424B3, 1 EFFECT, 2 10-K, 6 10-Q, 3 DEF 14A, 1 SC 13G, 2 SC 13D/A, 1 S-1 with the SEC between Apr 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 8-K Filing — 8-K · Apr 10, 2026
• 424B3 Filing — 424B3 · Apr 7, 2026
• MetaVia Inc. SEC Filing Effectiveness Notified — EFFECT · Apr 7, 2026 Risk: medium
  MetaVia Inc. filed an EFFECT form with the SEC on April 7, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 999
• MetaVia Pushes MASH, Obesity Drugs Amidst Mounting Losses — 10-K · Mar 26, 2026 Risk: high
  MetaVia Inc. (MTVA) reported continued net losses for the fiscal year ended December 31, 2025, as it remains a clinical-stage biotechnology company without reve
• MetaVia Inc. Files 8-K on Financial Results — 8-K · Mar 26, 2026
  MetaVia Inc. filed an 8-K on March 26, 2026, reporting its results of operations and financial condition under Item 2.02. This filing indicates the company is r
• 8-K Filing — 8-K · Dec 19, 2025
• 8-K Filing — 8-K · Dec 2, 2025
• 8-K Filing — 8-K · Nov 26, 2025
• 8-K Filing — 8-K · Nov 7, 2025
• MetaVia Narrows Losses Amid R&D Cuts, Cash Declines — 10-Q · Nov 6, 2025 Risk: high
  MetaVia Inc. (MTVA) reported a net loss of $3.377 million for the three months ended September 30, 2025, a significant improvement from the $5.652 million net l
• MetaVia Navigates Q2 with No Revenue, Relies on Private Placement — 10-Q · Aug 7, 2025 Risk: high
  MetaVia Inc. (MTVA) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue pharmaceutical development stage. The
• MetaVia Inc. Files 8-K: Regulation FD & Financials — 8-K · Aug 6, 2025 Risk: low
  On August 6, 2025, MetaVia Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. MetaVia Inc.
• MetaVia Inc. Files 8-K for Regulation FD and Financials — 8-K · Aug 4, 2025 Risk: low
  MetaVia Inc. filed an 8-K on August 4, 2025, to report information under Regulation FD and to file financial statements and exhibits. The company, formerly know
• MetaVia Inc. Files 8-K with Regulatory Updates — 8-K · Jul 9, 2025 Risk: low
  MetaVia Inc. filed an 8-K on July 9, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as NeuroBo Ph
• MetaVia Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jun 30, 2025 Risk: medium
  On June 30, 2025, MetaVia Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as NeuroBo Pharm
• MetaVia Sets June 30 Annual Meeting, Board Elections on Tap — DEF 14A · Jun 10, 2025 Risk: low
  MetaVia Inc. (MTVA) filed a DEF 14A on June 10, 2025, for its virtual 2025 Annual Meeting of Stockholders scheduled for June 30, 2025, at 10:00 a.m. Eastern Tim
• MetaVia Inc. Faces Delisting Concerns — 8-K · May 30, 2025 Risk: high
  MetaVia Inc. filed an 8-K on May 30, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly kno
• MetaVia Inc. Files 8-K, Former Names Revealed — 8-K · May 21, 2025 Risk: low
  On May 21, 2025, MetaVia Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 545 Concord Avenue, Suite 210,
• MetaVia Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · May 14, 2025 Risk: medium
  On May 8, 2025, MetaVia Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reporte
• MetaVia Inc. Q1 2025 10-Q Filed — 10-Q · May 14, 2025 Risk: low
  MetaVia Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., i
• MetaVia Inc. Files 8-K — 8-K · May 7, 2025 Risk: low
  MetaVia Inc. filed an 8-K on May 7, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as NeuroBo Pharmaceutical
• MetaVia Inc. Files 8-K with Financials — 8-K · Apr 22, 2025 Risk: low
  On April 22, 2025, MetaVia Inc. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific material events or dis
• MetaVia Inc. Files 8-K with Regulatory Updates — 8-K · Apr 15, 2025 Risk: low
  MetaVia Inc. filed an 8-K on April 15, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, an
• MetaVia Inc. Files 2024 10-K, Details Financials — 10-K · Mar 20, 2025 Risk: medium
  MetaVia Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations as a pharmaceutical preparations company. The filing detai
• MetaVia Inc. Files 8-K for Regulation FD Disclosure — 8-K · Jan 10, 2025 Risk: low
  On January 10, 2025, MetaVia Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes Financial Statem
• MetaVia Inc. Files 8-K Report — 8-K · Dec 18, 2024 Risk: low
  On December 18, 2024, MetaVia Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and includes financial statements
• MetaVia Inc. Files 8-K — 8-K · Nov 29, 2024 Risk: low
  MetaVia Inc. filed an 8-K on November 29, 2024, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as N
• NeuroBo Pharmaceuticals Files 8-K with Corporate Updates — 8-K · Nov 18, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on November 18, 2024, reporting events as of November 15, 2024. The filing indicates changes to its Articles of Incor
• SC 13G Filing — SC 13G · Nov 14, 2024
• NeuroBo Pharma Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  NeuroBo Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Gemphire Therapeutics Inc., reported financial resu
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Nov 4, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on November 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerl
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Oct 7, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Sep 30, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on September 30, 2024, reporting on its financial statements and exhibits. The company, formerly known as Gemphire Th
• Dong-A ST Amends NeuroBo Pharmaceuticals Stake — SC 13D/A · Sep 20, 2024 Risk: medium
  Dong-A ST Co., Ltd. filed an amendment (Amendment #7) to its Schedule 13D on September 20, 2024, regarding its holdings in NeuroBo Pharmaceuticals, Inc. The fil
• NeuroBo Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Sep 19, 2024 Risk: medium
  On September 18, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report to announce a submission of matters to a vote of its security holders. The filing does
• NeuroBo Pharmaceuticals Files Definitive Proxy Statement — DEF 14A · Aug 21, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 21, 2024, for its fiscal year ending December 31, 2024. The company, former
• NeuroBo Pharma Q2 2024: Assets $8.2M, Liabilities $4.9M — 10-Q · Aug 14, 2024 Risk: medium
  NeuroBo Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $8.221 million and total liabilities of $
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Aug 13, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on August 13, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Aug 6, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, to report on Regulation FD disclosures and financial statements. The company, formerly known as Ge
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Jul 30, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on July 30, 2024, to report on Regulation FD disclosures and financial statements. The filing indicates the company's
• NeuroBo Pharma Files S-1 for Potential Offering — S-1 · Jul 18, 2024 Risk: medium
  NeuroBo Pharmaceuticals, Inc. filed an S-1 registration statement on July 18, 2024, to offer securities. The company, formerly Gemphire Therapeutics Inc. until
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Jul 16, 2024 Risk: low
  On July 16, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine discl
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Jun 26, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on June 26, 2024, to report other events and financial statements. The company, formerly known as Gemphire Therapeuti
• NeuroBo Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · Jun 25, 2024 Risk: medium
  NeuroBo Pharmaceuticals, Inc. announced on June 23, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales
• Dong-A ST Files 13D/A for NeuroBo Pharmaceuticals — SC 13D/A · Jun 25, 2024 Risk: medium
  Dong-A ST Co., Ltd. has filed an amendment (Amendment #6) to its Schedule 13D for NeuroBo Pharmaceuticals, Inc. on June 25, 2024. This filing relates to the com
• NeuroBo Pharmaceuticals Files 8-K — 8-K · Jun 24, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. filed an 8-K on June 24, 2024, reporting other events and financial statements. The company, formerly known as Gemphire Therapeuti
• NeuroBo Pharmaceuticals Appoints New Officers and Directors — 8-K · Jun 7, 2024 Risk: medium
  NeuroBo Pharmaceuticals, Inc. announced on June 7, 2024, the appointment of Dr. Sang-Jin Song as Chief Medical Officer and Dr. Jian Li as Chief Scientific Offic
• NeuroBo Pharmaceuticals Files 8-K — 8-K · May 22, 2024 Risk: low
  On May 22, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
• NeuroBo Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. (MTVA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. NeuroBo Pharmaceuticals, Inc. filed a 10-Q report for the peri
• NeuroBo Pharmaceuticals Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 30, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. (MTVA) filed a Proxy Statement (DEF 14A) with the SEC on April 30, 2024. NeuroBo Pharmaceuticals will hold its 2024 Annual Meeting

Risk Profile

Risk Assessment: Of MTVA's 42 recent filings, 4 were flagged as high-risk, 12 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Metavia INC.'s most recent 10-K filing (Mar 26, 2026):

• Revenue: $0
• Net Income: Net Loss
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: Not Disclosed
• Operating Margin: N/A
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• DongStMember
• Min Young Kim
• Matthew Berger
• Michael Brandt
• Hyung Heon Kim
• Dr. Sang-Jin Song
• Dr. Jian Li
• Mr. David J. Lee
• Mr. David L. M. Ting

Industry Context

MetaVia operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on cardiometabolic diseases like MASH and obesity. The market is characterized by significant unmet needs and intense R&D efforts from both large pharmaceutical companies and smaller biotech firms. Key trends include the development of novel mechanisms of action, combination therapies, and the increasing focus on metabolic health.

Top Tags

financials (11) · disclosure (9) · 8-K (7) · 10-Q (5) · filing (5) · sec-filing (4) · corporate-governance (4) · corporate-update (4) · pharmaceuticals (4) · corporate-history (3)

Key Numbers

• Filing Acceptance Date: 2026-04-07 — Indicates when the SEC officially accepted the filing.
• Effectiveness Date: 2026-04-06 — Marks the date the registration statement became effective.
• Market Value of Non-Affiliate Common Stock: $3.0M — As of June 30, 2025, indicating a small market capitalization for MetaVia Inc.
• Shares Outstanding: 5.09M — As of March 20, 2026, representing the total common stock shares.
• Expected Data Readout: Q4 2026 — For DA-1726 Phase 1 clinical trial Parts 3a and 3b, a critical milestone for MetaVia Inc.
• Duration of Phase 2a Results: 16 weeks — Topline results for vanoglipel (DA-1241) in MASH patients, announced December 2024.
• Higher-Dose MAD Cohort: 48 mg — For DA-1726 Phase 1 clinical trial, extended to eight weeks in July 2025.
• Cash: $14.277M — Decreased from $16.017M at Dec 31, 2024, highlighting liquidity concerns.
• Accumulated Deficit: $146.9M — Indicates significant historical losses and contributes to going concern doubt.
• Net Loss (9 months): $11.043M — Reduced from $22.419M in 2024, showing improved loss management.
• Net Cash Used in Operations (9 months): $10.8M — Continues negative cash flow, a key factor in the going concern warning.
• R&D Expenses (Q3 2025): $1.914M — Significantly down from $4.517M in Q3 2024, reflecting cost control or program prioritization.
• Net Loss (Q3 2025): $3.377M — Improved from $5.652M in Q3 2024, but still a substantial loss.
• R&D Expenses (9 months): $6.561M — Substantially lower than $17.495M in 2024, indicating a major reduction in development spending.
• Revenue: $0 — for the three and six months ended June 30, 2025, indicating pre-revenue status

Related Companies

NRBO · NBIO

Frequently Asked Questions